GLP-1s are all the rage in pharma, not least because of the commercial force of prescription brands like Wegovy. Viatris, which has molded into a more innovative-thinking company, has outlined its intentions to compete in the space.
Viatris anticipates having a “significant role going forward” in the upcoming off-patent GLP-1 obesity and diabetes market, underlining that it has secured a crucial – yet unspecified – supply of active pharmaceutical ingredient for its planned assets and “certainly have invested in our capability to manufacture.”
“We are looking at developing multiple GLP-1s: semaglutide and liraglutide, as well as Eli Lilly’s Mounjaro (tirzepatide),” the firm’s management...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
